The BRD4 inhibitor Pelabresib (CPI-0610) has shown synergistic anticancer effects, when combined with Ruxolitinib, the current standard of care treatment in myelofibrosis patients, in 84 myelofibrosis patients in a Phase II clinical trial [72]. Here, BRD4 is linked to myelofibrosis.